Osteoporosis International

, Volume 15, Issue 6, pp 434–438

Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study

  • Julie A. Pasco
  • Mark A. Kotowicz
  • Margaret J. Henry
  • Kerrie M. Sanders
  • Ego Seeman
  • Geoffrey C. Nicholson
Original Article

DOI: 10.1007/s00198-003-1574-1

Cite this article as:
Pasco, J.A., Kotowicz, M.A., Henry, M.J. et al. Osteoporos Int (2004) 15: 434. doi:10.1007/s00198-003-1574-1

Abstract

In this population-based study, we evaluated the association between exposure to hormone therapy (HT), bone mineral density (BMD) and the prevalence of non-vertebral fractures. The study was set in a region located in southeastern Australia where complete fracture ascertainment was determined from radiological reports. Current HT use for at least 6 months was ascertained in women with non-vertebral fractures [median age 70.9 years; inter-quartile range (IQR) 66.5–75.9 years] and randomly selected controls (median age 70.8 years; IQR 65.2–75.0 years). Current HT use was documented in 20 of 262 cases and 49 of 364 controls. The odds ratio (OR) for non-vertebral fracture associated with HT use was 0.53 (95% CI 0.31–0.92). HT use was associated with 2.6–7.5% higher BMD at axial and appendicular sites. HT use is associated with a halving of risk for non-vertebral fractures and higher BMD.

Keywords

Bone mineral density Fracture Hormone therapy Population-based study Postmenopausal women 

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2004

Authors and Affiliations

  • Julie A. Pasco
    • 1
  • Mark A. Kotowicz
    • 1
  • Margaret J. Henry
    • 1
  • Kerrie M. Sanders
    • 1
  • Ego Seeman
    • 2
  • Geoffrey C. Nicholson
    • 1
  1. 1.Department of Clinical and Biomedical Sciences: Barwon HealthThe University of MelbourneGeelongAustralia
  2. 2.Department of MedicineThe University of Melbourne, Austin and Repatriation Medical CentreHeidelberg, VictoriaAustralia

Personalised recommendations